# Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct02683746` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02683746](<https://clinicaltrials.gov/study/NCT02683746>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02683746

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 308 participants.

## Technical summary

Registry record NCT02683746. Randomized; double masking; primary purpose treatment. Start 2016-03-16 (actual); primary completion 2017-04-03 (actual). Results posted on 2018-05-30.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 308 participants (enrolled count; ClinicalTrials.gov record NCT02683746, source copy `cardio:ctgov-nct02683746-2019-07-23`, retrieved 2026-10-26)
- Started: 2016-03-16 (actual) (ClinicalTrials.gov record NCT02683746, source copy `cardio:ctgov-nct02683746-2019-07-23`, retrieved 2026-10-26)
- Primary completion: 2017-04-03 (actual) (ClinicalTrials.gov record NCT02683746, source copy `cardio:ctgov-nct02683746-2019-07-23`, retrieved 2026-10-26)
- Completion: 2017-05-15 (actual) (ClinicalTrials.gov record NCT02683746, source copy `cardio:ctgov-nct02683746-2019-07-23`, retrieved 2026-10-26)
- Results first posted: 2018-05-30 (ClinicalTrials.gov record NCT02683746, source copy `cardio:ctgov-nct02683746-2019-07-23`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02683746, source copy `cardio:ctgov-nct02683746-2019-07-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02683746-2019-07-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Lyophilized albiglutide DCC pen injector
- Intervention (Drug): Lyophilized albiglutide DCC pen injector matching placebo
- Intervention (Drug): Albiglutide liquid auto-injector
- Intervention (Drug): Albiglutide liquid auto-injector matching placebo
- Lead sponsor: GlaxoSmithKline
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: GlaxoSmithKline (`cardio:org-glaxosmithkline`)

## Provenance

Content hash: 4c97823d524bb307fdc1a3ed77a912400a4acd2a7f50b73c70be9f7c2616fe0a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
